Notice: This company has been marked as potentially delisted and may not be actively trading. NYSE:PKI Revvity (PKI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Revvity Stock (NYSE:PKI) 30 days 90 days 365 days Advanced Chart Ad InvestorPlaceRevolutionary Tech Alert: How Elon Musk is Changing Lives"Elon Musk's Neuralink just received FDA breakthrough status for a revolutionary device designed to restore vision to those who've lost it entirely. And the first human clinical trials have opened for recruitment. Click here to see it. Get Revvity alerts:Sign Up Key Stats Today's Range N/A50-Day Range$115.24▼$137.1152-Week Range N/AVolume1.63 million shsAverage Volume851,117 shsMarket Capitalization$14.57 billionP/E Ratio15.01Dividend Yield0.24%Price Target$54.00Consensus RatingBuy Company OverviewRevvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.Read More… Revolutionary Tech Alert: How Elon Musk is Changing Lives (Ad)"Elon Musk's Neuralink just received FDA breakthrough status for a revolutionary device designed to restore vision to those who've lost it entirely. And the first human clinical trials have opened for recruitment. Click here to see it. Revvity Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks87th Percentile Overall ScorePKI MarketRank™: Revvity scored higher than 87% of companies evaluated by MarketBeat, and ranked 157th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingRevvity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRevvity has received no research coverage in the past 90 days.Read more about Revvity's stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth17.71% Earnings GrowthEarnings for Revvity are expected to grow by 17.71% in the coming year, from $4.97 to $5.85 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revvity is 15.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.77.Price to Earnings Ratio vs. SectorThe P/E ratio of Revvity is 15.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 140.14.Price to Earnings Growth RatioRevvity has a PEG Ratio of 0.50. PEG Ratios below 1 indicate that a company could be undervalued. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PKI. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldRevvity has a dividend yield of 0.24%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthRevvity does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Revvity is 3.65%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Revvity will have a dividend payout ratio of 4.79% next year. This indicates that Revvity will be able to sustain or increase its dividend.Read more about Revvity's dividend. Sustainability and ESG3.5 / 5Environmental Score-1.99 Short InterestThere is no current short interest data available for PKI. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for PKI on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Revvity insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.52% of the stock of Revvity is held by insiders.Percentage Held by Institutions85.22% of the stock of Revvity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Revvity's insider trading history. Receive PKI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revvity and its competitors with MarketBeat's FREE daily newsletter. Email Address PKI Stock News HeadlinesRevvity, Inc. (RVTY)July 19, 2024 | finance.yahoo.comRevvity Inc PKIFebruary 13, 2024 | morningstar.comKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… October 3, 2024 | Paradigm Press (Ad)Revvity Launches EONIS Q System Enabling Faster, Simplified Newborn Screening for SMA and SCIDDecember 1, 2023 | businesswire.comRevvity Stock (NYSE:RVTY), Analyst Ratings, Price Targets, PredictionsNovember 1, 2023 | benzinga.comRevvity, Inc. and Element Biosciences, Inc. Pioneer Next-Generation Sequencing Kits Market with Innovative Genomic Analysis SolutionsOctober 29, 2023 | finance.yahoo.comRevvity (RVTY) Beats on Q2 Earnings, Lowers '23 EPS ViewAugust 2, 2023 | finance.yahoo.comRevvity (NYSE: PKI)August 1, 2023 | fool.comSee More Headlines PKI Stock Analysis - Frequently Asked Questions How were Revvity's earnings last quarter? Revvity, Inc. (NYSE:PKI) issued its earnings results on Thursday, May, 11th. The medical research company reported $1.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.07 by $0.06. The medical research company earned $674.87 million during the quarter, compared to analysts' expectations of $686.30 million. Revvity had a net margin of 28.94% and a trailing twelve-month return on equity of 11.17%. Is Revvity doing a stock buyback? Revvity's board approved a stock buyback plan on Thursday, May 11th 2023, which authorizes the company to buy back $600,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 4.1% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its stock is undervalued. Does Revvity have any subsidiaries? The following companies are subsidiaries of Revvity: BioLegend, Immunodiagnostic Systems, Nexcelom Bioscience, SIRION Biotech, Oxford Immunotec, Horizon Discovery, Cisbio.com, and others. What other stocks do shareholders of Revvity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Revvity investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), Home Depot (HD) and Bristol-Myers Squibb (BMY). Company Calendar Last Earnings5/11/2023Today10/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:PKI CUSIP71404610 CIK31791 Webwww.perkinelmer.com Phone(781) 663-6900Fax781-663-5985Employees16,700Year Founded1937Price Target and Rating Average Stock Price Target$54.00 High Stock Price Target$54.00 Low Stock Price Target$54.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$7.68 Trailing P/E Ratio15.01 Forward P/E RatioN/A P/E Growth0.5Net Income$569.18 million Net Margins28.94% Pretax Margin13.81% Return on Equity11.17% Return on Assets5.83% Debt Debt-to-Equity Ratio0.48 Current Ratio2.43 Quick Ratio2.15 Sales & Book Value Annual Sales$3.31 billion Price / Sales0.00 Cash FlowN/A Price / Cash Flow9.88 Book Value$58.49 per share Price / BookN/AMiscellaneous Outstanding Shares126,410,000Free Float125,755,000Market Cap$14.57 billion OptionableOptionable Beta1.10 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NYSE:PKI) was last updated on 10/3/2024 by MarketBeat.com Staff From Our PartnersAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredNo matter the outcome of the election, it could be a death sentence for your wealth...In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional inv...Allegiance Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredShedding light on a dark secretElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revvity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revvity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.